Rheumatoid Arthritis Market

Rheumatoid Arthritis Market Outlook (2023 to 2033)

The Global revenue from the Rheumatoid Arthritis Market was about US$ 687.9 Million in 2022, with the global market expected to grow at a CAGR of 5.4% to reach a valuation of about US$ 1.2 Billion by the end of 2033.

As assessed by Persistence Market Research, the serology test segment held a market share of around 67.5% in the global market, in 2022. Overall, rheumatoid arthritis market sales account for around 12.0% of revenue share in the global autoimmune disease diagnostics market, which was valued at US$ 5.7 Billion in 2022.

Rheumatoid arthritis (rheumatoid arthritis) is an autoimmune disease that causes swelling, warmth, and pain by inflaming the connective tissue, joints, muscles, tendons, and fibrous tissue. It can also cause by infections, injuries, normal wear and tear, or genetics. Rheumatoid arthritis is predominantly found in the hands, wrists, and feet. In rheumatoid arthritis, the immune system recognizes its own tissues as antigens and begins producing antibodies against them, causing inflammation. Rheumatoid arthritis is more widespread in women than in men.

Rheumatoid arthritis can be diagnosed through two methods, namely X-ray imaging and blood tests/serology test. The blood test regularly used to diagnose rheumatoid arthritis include rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), and erythrocyte sedimentation rate (ESR), antinuclear antibody (ANA), and uric acid test.

Sales Analysis of Market from 2014 to 2022 Vs Market Outlook for 2023 to 2033

The global rheumatoid arthritis market recorded a historic CAGR of 4.2% in the last 8 years from 2014 to 2022 due to primarily the adoption of off-label arthritis diagnostic procedures.

Diagnosing rheumatoid arthritis quickly is important because it is incurable. Early treatment and support can prevent it from worsening by implementing lifestyle changes (avoidance of smoking, well-balanced diet, and exercise) supportive treatments, medications, and surgery to reduce the joint damage and the impact of the condition.

• According to World Health Organisation (WHO) 2021, rheumatoid arthritis affects up to 14 Million people.
• According to a published article on a time-trend incidence of rheumatoid arthritis in Frontiers in Medicine in 2022, rheumatoid arthritis is primarily typical among 5% of the population suffering from chronic inflammatory arthritis (IA).

The rising prevalence of rheumatoid arthritis and other autoimmune diseases has necessitated the development of rapid diagnostic test solutions that would reduce the time and effort required during sample testing. As a result, manufacturers of autoimmune disease test kits are focusing on the commercialization of novel rapid diagnostic test kits with high specificity and sensitivity. The trend of diagnosing rheumatoid arthritis through multiple tests (such as rheumatoid factor and antinuclear antibodies tests) is gaining popularity and is largely adopted by physicians due limited specificity of diagnostic tests. Various combined testing methods are used to monitor rheumatoid arthritis treatment efficacy. Thus, it is expected that the commercialization of rapid diagnostic test kits will increase the demand for rheumatoid arthritis diagnostic test kits and rheumatoid arthritis treatment efficacy monitoring test kits.

There is a high level of off-label prescriptions of anti-inflammatory drugs as treatment owing to the unavailability of specific treatments. Such increasing off-label prescription requires continuous monitoring, which could be conducted through various testing methods such as salicylate level count, muscle enzyme test (CPK, Aldolase), and creatinine test.

The trend of diagnosing rheumatoid arthritis through multiple tests (such as a combination of rheumatoid factor and antinuclear antibodies tests) is gaining popularity and is largely adopted by physicians due limited specificity of diagnostic tests. Various combined testing methods are used to monitor rheumatoid arthritis treatment efficacy.

How Can the Global Market Grow?

“Active Participation of Government”

Increasing spending by government bodies to develop novel and cost-effective drugs for rheumatoid arthritis surveillance and treatment are among the predominant factors expected to drive the growth of the rheumatoid arthritis market during the analysis period. Government bodies are investing in research and development activities to decrease their burden on rheumatoid arthritis surveillance and treatment.

Government support in terms of diagnosis and surveillance of the rheumatoid arthritis epidemic plays an important role in controlling the spread of rheumatoid arthritis globally. Increasing spending on tracking epidemiology and surveillance of rheumatoid arthritis is anticipated to promote the growth of the rheumatoid arthritis diagnosis over the forecast period.

• In 2020, the Centers for Disease Control and Prevention (CDC) showed data on statistics of arthritic patients and arthritis affecting factors on quality of life. The data was collected from the national health interview survey and behavioral risk factor surveillance system. Other Centers for Disease Control and Prevention (CDC) programs like Arthritis Program, Chronic Disease Self-Management Program, and Centers for Disease Control and Prevention-Recommended Physical Activity Programs are helping to raise awareness and diagnosis of rheumatoid arthritis.

Currently, there is no effective treatment available for rheumatoid arthritis. However, physicians usually prescribe anti-inflammatory drugs as an off-label treatment, which helps in reducing joint inflammation among patients suffering from rheumatoid arthritis. Such increased level of off-label prescription by physicians has been leading to the rise in demand for rheumatoid arthritis treatment efficacy monitoring test kits and rheumatoid arthritis diagnosis test kits, globally. The anti-cyclic citrullinated peptide (anti-CCP) test segment and antinuclear antibody (ANA) test segment are anticipated to lead the market owing to high specificity and sensitivity.

Can the Market Growth Be Affected in Any Way?

“Limited Specificity and Sensitivity of Rheumatoid Arthritis Tests Kits”

Test kits available in the market have limited specificity and sensitivity towards rheumatoid arthritis, which is a dominant factor restraining the growth of rheumatoid arthritis test kits currently. Conventional test methods such as erythrocyte sedimentation rate (ESR) and rheumatoid factor (RF) tests have limited specificity and sensitivity. Innovative diagnostic test kits such as antinuclear antibody (ANA) tests and anti-cyclic citrullinated peptide (anti-CCP) are providing test results with high specificity and sensitivity. Increasing the adoption of these tests is a significant challenge, because of their high costs.

Traditional tests used to diagnose rheumatoid arthritis have limited specificity and sensitivity. Thus, this leads to a maximum false positive rate in test outcomes. Such a maximum rate of false positive outcomes would deter the reliability of tests, ultimately affecting the growth of the rheumatoid arthritis diagnosis test kits market. The positivity ratio of the rheumatoid arthritis test was around 65% (true positive and false positive) owing to the widespread use of traditional rheumatoid arthritis testing methods such as RF test, ESR test, among other.

Rheumatoid arthritis test kits available in the market are facing challenges in terms of specificity and sensitivity, owing to difficulties in diagnosing the root cause of rheumatoid arthritis. The physicians adopted combinational tests to diagnose and monitor the progress of rheumatoid arthritis. Hence, the diagnostic cost is increasing for combined test kits.

Country-wise Insights

Why Is the United States Market Booming?

“Government Funding and Arthritis Programs Will Increase rheumatoid arthritis Awareness”

The United States market held around 14.5% market share of the global market in 2022 due to increasing awareness with the help of government funding.

• According to Centers for Disease Control and Prevention (CDC) data from 2021, 58.5 million adults (24%) in the United States have arthritis, which is a significant cause of work impairment and has annual costs for medical care and lost wages of about US $303.5 billion. The most common types of arthritis are rheumatoid arthritis, lupus, gout, and osteoarthritis. In the United States, 57.3% of adults have arthritis and are employed (18 to 64 years). Their ability to engage in physical activity and labor may be restricted or eliminated by arthritis. In fact, 8 million working-age adults claim that their capacity to work is hampered by arthritis.

The Centers for Disease Control and Prevention (CDC) conducts research and funds programs to help people with arthritis work and do other everyday activities, manage their own care, have less pain, and avoid or postpone disability. The Centers for Disease Control and Prevention (CDC) has provided funding to support arthritis self-management education, and physical activity programs, raising awareness about rheumatoid arthritis detection and treatment.

• For instance, insurance claims worth the musculoskeletal conditions (such as osteoarthritis, joint pain, and lower back pain) were US$ 22.1 Million in New Hampshire in 2019. Hence, the New Hampshire Arthritis Program collaborated with Blue Shield and Anthem Blue Cross (insurance companies), and the State Department of Administrative Services to provide Self-Directed Enhanced and Walk with Ease Self-Directed programs to all state employees, dependents, and retirees.

Will Germany Be a Lucrative Market for Rheumatoid Arthritis Diagnosis Tests?

“Diagnosis and Management of Juvenile Idiopathic Arthritis”

Germany market held around 6.3% market share of the global market in 2022 due to focusing on the diagnosis and management of juvenile idiopathic arthritis.

• According to a 2016 PLOS journal article on health quality for long-term in German juvenile idiopathic arthritis patients in comparison to the general population of Germany, juvenile idiopathic arthritis is typical in Germany. Every year, about 7 out of every 100 children in Germany are newly diagnosed with juvenile idiopathic arthritis. In contrast, the global annual incidence of juvenile idiopathic arthritis ranges between 0.8 and 22.6 per 100 children.

According to a 2018 article in Pediatric Rheumatology on practice and based on consensus strategies of diagnosis and management in systemic juvenile idiopathic arthritis in Germany, auto-inflammatory disease like systemic juvenile idiopathic arthritis (SJIA) is related to chronic arthritis. Early prognosis, diagnosis, and appropriate treatment of SJIA are advisable to avoid any future complications. Pediatric Rheumatology Society in Germany (GKJR) and its PRO-KIND Initiative help to establish harmonized diagnostic and therapeutic strategies based on consensus viewpoints in patients with suspected juvenile idiopathic arthritis, also patients with probable and definitive systemic juvenile idiopathic arthritis (SJIA) in Germany.

Category-wise Insights

Which Type of Test Is Driving Demand Within the Global Market?

“Serological Test Is Crucial in Early Detection and Differentiation of rheumatoid arthritis is growing”

By type of test, serology test holds 67.5% share of the global market in 2022 due to early diagnosis and differentiation of rheumatoid arthritis.

Serology tests are useful in detecting antibodies that are produced after a person is exposed to a foreign substance or microorganism. In a few cases, the antibodies produced act against the person's own tissues. As a result, serology tests can aid in the diagnosis of autoimmune and immunodeficiency disorders.

Which End User Is Helping to Expand the Global Market?

“Lab Tests Are Crucial in Diagnosis and Management of the Disease Without Hospitalisation”

By end users, the diagnostic laboratories held around 41.6% share of the global market in 2022 because of preference for diagnostic labs to conduct diagnostic tests critical for detecting the disease's initial stages and management.

Laboratory diagnostics is a subset of clinical diagnostics that studies and evaluates the body's cellular and biochemical blood composition, biological characteristics of tissue fluids, diagnoses pathogenic agents and related diseases, and overall physiological state. Hence, diagnostic laboratories are important for the management of diseases conditions without getting admitted in hospitals.

Early detection and treatment with disease-modifying anti-rheumatic drugs (DMARDs) is critical for disease control and the prevention of joint injury and disability. The more distinguishing features of rheumatoid arthritis, such as joint erosions, rheumatoid nodules, and other extra-articular manifestations, are seen primarily in patients with longstanding, poorly controlled disease and are frequently absent at the time of initial presentation.

As a result, diagnostic lab tests are critical for detecting the disease's initial stages. A careful history and physical examination, as well as selected laboratory testing, are required for the initial evaluation of such patients in order to identify features that are characteristic of rheumatoid arthritis or that suggest an alternative diagnosis (clinical manifestations of rheumatoid arthritis and differential diagnosis).

Competition Landscape

Companies that produce rheumatoid arthritis test kits are targeting the global market through their extensive distribution network, making the product available at every level of the value chain. To meet the growing demand for rheumatoid arthritis diagnosis, manufacturers are focusing on the acquisition of manufacturing companies that are especially regulating products in rheumatoid arthritis. Key manufacturers are also focusing on innovative development, such as biomarker-based diagnostic methods for rheumatoid arthritis, which are expected to create new growth opportunities for rheumatoid arthritis test kit manufacturers.

A few examples of key strategies by the key players:

• In January 2019, Abbott Diagnostics announced that it has acquired Cepha Valve Technologies, Inc.
• On 25 February 2019, Roche announced that it is about to acquire Spark Therapeutics at a price of $114.50 per share.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the rheumatoid arthritis market, which are available in the full report.

Rheumatoid Arthritis Diagnosis Test Industry Report Scope

Key Segments Covered in Rheumatoid Arthritis Industry Research

Test Type

• Serology Tests
  • Erythrocyte Sedimentation rheumatoid arthritis (ESR)
  • Rheumatoid Factor (RF)
  • Anti–cyclic Citrullinated Peptide (anti-CCP)
  • Antinuclear Antibody (ANA)
  • Uric Acid
  • Other Test
• Monitoring rheumatoid arthritis Treatment Efficiency Tests
  • Salicylate Level Count
  • Muscle Enzyme Test
  • Creatinine Test

End User

• Hospitals
• Diagnostic Laboratories
  • Private Laboratories
  • Public Laboratories
• Ambulatory Surgical Centers

Region

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa (MEA)

To know more about delivery timeline for this report Contact Sales